A Phase 3 interventional study of Yellow fever vaccine (live) in Yellow Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 4 sites in Japan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Yellow Fever Vaccine in Yellow Fever — 3 open to participants now, 7 under way, 1 of them phase 3. Yellow Fever Vaccine · Yellow Fever.
Among the 18 studies testing Yellow Fever Vaccine in Yellow Fever, this one is the 9th largest by enrollment, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 18th registered.
52 studies on the registry are indexed under Yellow Fever; 10 are open to participants now.
Browse Yellow Fever studies →3 of the 18 studies testing Yellow Fever Vaccine in Yellow Fever are open now, in 2 countries. Recruiting first, the newest first:
Leiden University Medical Center · Sites in Netherlands
Ages 18–50 · Healthy volunteers
International Centre for Diarrhoeal Disease Research, Bangladesh · Sites in Bangladesh
Ages 9 mo–12 mo · Healthy volunteers
ANRS, Emerging Infectious Diseases
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Yellow Fever Vaccine: first FDA approval 1999 (Yf-Vax). What it is approved for, and how studies give it, is on its page →
Of the 7 Yellow Fever studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 6 · Phase 4 4
First in 2004; this study’s year is marked. 3 started in 2025.
This study's enrollment of 254 is above the median of 112 across 43 interventional studies indexed under Yellow Fever.
Median enrollment 181 across the 18 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
10 studies in Yellow Fever by Sanofi: none open now, 3 under way, 1 of them phase 3. Of 7 finished, 3 (43%) have results posted.
Among the 10 studies in Yellow Fever by Sanofi, this one is one of 3 that started in 2025, is one of 4 in phase 3, and was the 10th registered.
Sanofi’s Yellow Fever studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Yellow Fever Vaccine in Yellow Fever, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 10 in Yellow Fever:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and immunogenicity of vYF in adults aged 18 years and over in Japan.
Study details include:
Number of Participants:
A total of 254 participants is expected to be included in the study with the aim to obtain a total of 203 evaluable participants.
Study Arms and Duration:
Eligible participants will receive, subcutaneously, a single dose of vYF vaccine on Day 1.
The duration of each participation will be approximately 1 month for each participant.
Duration of study participation: approximately 1 month for each participant
Inclusion Criteria:
Aged from 18 years on the day of inclusion*
* "From 18 years" means from the day of the 18th birthday
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
OR
. Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration.
A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before any dose of study intervention on Day 01 and will be repeated on Day 29 to confirm the participant is still not pregnant within the 28 days of vaccine administration.
- form (ICF) has been signed and dated Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Chronic illness* that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion, including , such as leukemia, or lymphoma
* Chronic illness may include, but is not limited to cardiac disorders, renal disorders, auto-immune disorders, diabetes, psychiatric disorders or chronic infection
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One single dose of vYF will be administered subcutaneously at the 1st visit
Biological: Yellow fever vaccine (live)
Pharmaceutical form:Powder and diluent for suspension for injection-Route of administration:Subcutaneous
Also known as: vYF vaccine
Percentage of participants with seroconversion to YF virus in YF-naive participants
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)
Time frame: 28 days after one dose of vYF vaccine
Percentage of participants with seroprotection to YF virus
Seroprotection is defined as NAb titers ≥ 10 (1/dil) at the corresponding timepoint
Time frame: At Day 01 and Day 29
Percentage of participants with seroconversion to YF virus
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)
Time frame: 28 days after one dose of vYF vaccine
Geometric Mean Titers (GMTs) of neutralizing antibodies against YF virus
Antibody titers are expressed as GMTs
Time frame: At Day 01 and Day 29
Geometric Mean Titers Ratio (GMTRs) of neutralizing antibodies against YF virus
GMTRs Day 29/Day 01
Time frame: At Day 01 and Day 29
Number of participants with immediate adverse events
Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination
Time frame: Within 30 minutes after vaccination
Number of participants with solicited injection site reactions
Solicited injection site reactions: injection site pain, injection site erythema, injection site swelling
Time frame: Within 7 days after vaccination
Number of participants with solicited systemic reactions
Solicited systemic reactions: fever, headache, fatigue, myalgia
Time frame: Within 14 days after vaccination
Number of participants with unsolicited adverse events (AEs), including adverse events of special interest (AESIs)
Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions, including AESIs
Time frame: Within 28 days after vaccination
Number of participants with serious adverse events (SAEs) including serious AESIs
SAEs including serious AESIs
Time frame: Within 28 days after vaccination
Number of participants with related SAEs and all deaths
Related SAEs and all deaths
Time frame: From Day 01 to Day 29 after vaccination
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Oct 2025 to primary completion in Dec 2025, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Yellow Fever Vaccine
Sanofi Pasteur, a Sanofi Company →